BFM
JANX icon

Boothbay Fund Management’s Janux Therapeutics JANX Stock Holding History

Boothbay Fund Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-106,500
Closed -$4.84M – 1717
2024
Q3 		$4.84M Buy
+106,500
New +$4.63M 0.11% 263

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boothbay Fund Management's JANX Position: Q4 2025 in Review

Boothbay Fund Management sold out of Janux Therapeutics (JANX) in Q4 2025, closing a stake of 12,005 shares — an estimated $293K sold.

Boothbay Fund Management first reported a position in JANX in Q4 2024 and held it in 4 quarters. The position peaked at $1.44M in Q4 2024. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

  • Boothbay Fund Management reported no remaining Janux Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 12,005 Janux Therapeutics shares in Q4 2025, an estimated $293K.
  • Boothbay Fund Management first reported a position in Janux Therapeutics in Q4 2024 and held it in 4 quarters.
  • Boothbay Fund Management's Janux Therapeutics position peaked at $1.44M in Q4 2024.
  • 176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.